thalidomide-o-peg-2-propargyl

Thalidomide-O-PEG2-propargyl (E3 Ligase Ligand-Linker Conjugates 32) is a chemical compound that has been synthesized as a conjugate of an E3 ligase ligand and a linker. It incorporates the cereblon ligand based on Thalidomide, along with a 2-unit PEG linker. This compound is specifically designed for use in PROTAC technology, which utilizes ligand-induced protein degradation [1].

Thalidomide-PEG4-Propargyl (Thalidomide-O-PEG4-Propargyl) is a synthetic E3 ligase ligand-linker conjugate containing a Thalidomide-based cereblon ligand and a linker which can be used in PROTAC technology[1].

Thalidomide-O-CH2CONH-CH2COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based CRBN ligand and linker used in PROTAC technology.

Thalidomide-O-amido-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate, integrating a Thalidomide-based cereblon ligand with a linker, suitable for PROTAC synthesis.

Thalidomide-O-amido-C4-NH2 TFA (E3 ligase Ligand-Linker Conjugates 19 TFA) is a synthesized compound that functions as an E3 ligase ligand-linker conjugate.

Thalidomide-propargyl, a Thalidomide-derived Cereblon ligand, facilitates the recruitment of Cereblon. It can be attached to the protein ligand via a linker, producing IMiD-containing PROTACs.

Thalidomide-linker 9 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

Thalidomide-O-amido-PEG3-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 3 (TFA)) is a synthesized E3 ligase ligand-linker conjugate incorporating a Thalidomide-based cereblon ligand and a 3-unit PEG linker, used in PROTAC technology.

Thalidomide-O-amido-PEG2-C2-NH2 TFA (E3 Ligase Ligand-Linker Conjugates 24 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating the Thalidomide-based cereblon ligand and a 2-unit PEG linker, utilized in PROTAC technology.

Thalidomide-O-COOH (Cereblon ligand 3) is a Thalidomide-based Cereblon ligand utilized for recruiting the CRBN protein and can be linked to a protein ligand via a linker to create PROTACs.

Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA) is a synthesized E3 ligase ligand-linker conjugate comprising a Thalidomide-based cereblon ligand and a linker.

Thalidomide-O-C6-NH2 hydrochloride (4-((6-aminohexyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione hydrochloride) is a synthesized E3 ligase ligand-linker conjugate.

Thalidomide-O-amido-C3-NH2 TFA (Cereblon Ligand-Linker Conjugates 16 TFA) is a synthesized E3 ligase ligand-linker conjugate incorporating a Thalidomide-based cereblon ligand and a linker used in PROTAC technology.

Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride, incorporating an E3 ligase ligand and a linker, can be used as an immunomodulator for the treatment of cancer.

DSPE-PEG-2-Aminoethyl-alpha-mannopyranoside (MW 2000) is a polyethylene glycol (PEG) derived linker used in the synthesis of proteolysis targeting chimeras (PROTACs) [1].

Bis-propargyl-O-PEG17 is a PEG-based linker for PROTACs that connects two essential ligands, crucial for forming PROTAC molecules, facilitating selective protein degradation through the ubiquitin-proteasome system within cells.

Thalidomide-O-C4-COOH is a synthetic conjugate compound that functions as an E3 ligase ligand-linker, combining a cereblon ligand derived from Thalidomide and a linker used in [PROTAC] technology.

N-methyl-N'-methyl-O-(m-PEG4)-O'-(propargyl-PEG4)-Cy3 is a polyethylene glycol (PEG)-based linker utilized in the synthesis of proteolysis targeting chimeras (PROTACs) [1].

Thalidomide-4-O-C10-NH2 hydrochloride, a Thalidomide-based cereblon ligand, facilitates the recruitment of the CRBN protein. This compound can be conjugated with a protein ligand via a linker to synthesize PROTACs [1].

Thalidomide-5-O-C3-NH2 hydrochloride, a Thalidomide-based cereblon ligand, facilitates CRBN protein recruitment and can be conjugated to a protein ligand via a linker to synthesize PROTACs [1].

Thalidomide-5-O-C5-NH2 hydrochloride, a Thalidomide-derived cereblon ligand, facilitates the recruitment of CRBN protein and can be conjugated via a linker to form PROTACs [1].

Thalidomide-5-O-C6-NH2 hydrochloride, a Thalidomide-based cereblon ligand, facilitates the recruitment of CRBN protein and can be conjugated via a linker to another ligand to form proteolysis-targeting chimeras (PROTACs) [1].

Thalidomide-5-O-C7-NH2 hydrochloride, a Thalidomide-based cereblon ligand, facilitates CRBN protein recruitment. This compound can be tethered to a protein-targeting ligand using a linker, enabling the formation of PROTACs [1].

Thalidomide-NH-CBP p300 ligand 2 (P-007) is a PROTAC-based compound engineered to degrade the proteins CBP and p300, functioning as a molecular antagonist (WO2020173440).

Thalidomide-O-C8-Boc is a Cereblon ligand derived from Thalidomide, primarily employed in the recruitment of CRBN protein. This ligand can be linked to a protein ligand via a linker to create PROTACs.

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthetic conjugate that combines a Thalidomide-based cereblon ligand and a linker, commonly utilized in PROTAC technology. This compound serves as a connector between the target protein and the E3 ligase, facilitating targeted protein degradation.

Dioxoisoindolin-O-PEG-OH (MW 2000) is a polyethylene glycol (PEG)-based linker used in the synthesis of PROTACs (proteolysis targeting chimeras)[1].

Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc is a synthesized conjugate functioning as an E3 ligase ligand-linker, incorporating the cereblon ligand derived from Thalidomide and a linker, and is utilized in the synthesis of PROTAC BET degraders.

Propargyl-PEG4-O-C1-Boc is a PEG-based linker for PROTACs that joins two essential ligands, facilitating selective protein degradation via the ubiquitin-proteasome system within cells.

Thalidomide-O-C8-NH2 hydrochloride is a chemical compound consisting of a synthesized E3 ligase ligand-linker conjugate. This compound incorporates a cereblon ligand derived from Thalidomide, as well as a linker employed in PROTAC technology.

Thalidomide-O-amido-C4-NH2 (Cereblon Ligand-Linker Conjugates 6) is a synthesized compound combining a Thalidomide-based cereblon ligand with a linker, serving as an E3 ligase ligand-linker conjugate for the synthesis of PROTACs[1].

Thalidomide-O-C2-acid, designed by synthesizing an E3 ligase ligand-linker conjugate, comprises a cereblon ligand derived from Thalidomide and a linker commonly used in PROTAC technology.

Thalidomide-O-C10-NH2 is a synthetic E3 ligase ligand-linker conjugate combining a cereblon ligand derived from Thalidomide with a linker crucial for PROTAC technology.

Thalidomide-O-amide-C5-NH2 is a chemically synthesized E3 ligase ligand-linker conjugate, combining a cereblon ligand derived from Thalidomide with a linker commonly employed in PROTAC technology.

Thalidomide-O-C7-acid is a compound synthesized as an E3 ligase ligand-linker conjugate, consisting of a cereblon ligand derived from Thalidomide and a linker commonly used in PROTAC technology.

Thalidomide-O-amido-PEG3-C2-NH2 (Cereblon Ligand-Linker Conjugates 3) is an E3 ligase ligand-linker conjugate developed using a Thalidomide-based cereblon ligand and a 3-unit PEG linker, synthesized specifically for use in PROTAC technology.

Thalidomide-O-amido-PEG4-propargyl is a polyethylene glycol (PEG)-based linker used in the synthesis of proteolysis targeting chimeras (PROTACs)[1].

Thalidomide-O-PEG4-azide is a PEG-based PROTAC linker utilized in PROTAC synthesis[1].

Thalidomide-O-C6-COOH is a synthetic conjugate that combines a Thalidomide-derived cereblon ligand with a PROTAC technology linker (E3 ligase ligand-linker).

Thalidomide-5-O-C10-NH2 hydrochloride, a Thalidomide-based cereblon ligand, facilitates the recruitment of CRBN protein and, when linked to a protein ligand, forms PROTACs [1].

Thalidomide-5-O-C12-NH2 hydrochloride, a Thalidomide-based cereblon ligand, facilitates the recruitment of CRBN protein and, when linked to a ligand for protein, forms PROTACs [1].

Thalidomide-O-C8-NH2 is a chemically synthesized conjugate that combines a cereblon ligand derived from Thalidomide with a linker utilized in PROTAC technology. It functions as an E3 ligase ligand-linker conjugate.

Propargyl-O-C1-amido-PEG4-C2-NHS ester is a non-cleavable 4-unit PEG linker used in antibody-drug conjugation (ADC) to link antibodies with drugs.

Thalidomide-O-amido-PEG4-C2-NH2 is a synthesized conjugate combining a Thalidomide-based cereblon ligand with a (PROTAC) technology linker, acting as an E3 ligase ligand-linker conjugate to enable targeted protein degradation.

Thalidomide-O-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12F36V and BET[1].

Thalidomide-O-amido-PEG-C2-NH2 is a synthesized conjugate formulation designed as an E3 ligase ligand-linker conjugate, incorporating a cereblon ligand based on Thalidomide and a linker component commonly used in PROTAC technology.

(2-Pyridyldithio)-PEG4-propargyl is a polyethylene glycol (PEG)-based linker engineered for the synthesis of proteolysis-targeting chimeras (PROTACs) [1].

Tos-PEG2-O-Propargyl is a polyethylene glycol (PEG)-based proteolysis targeting chimera (PROTAC) linker, frequently used for synthesizing Thalidomide-O-PEG2-propargyl[1].

Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride, a synthesized E3 ligase ligand-linker conjugate, incorporates a cereblon ligand derived from Thalidomide and a 3-unit PEG linker. This compound is specifically designed for use in PROTAC technology, which utilizes small molecules to induce protein degradation [1].